Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valsartan + Hydrochlorothiazide vs Valsartan in Hypertensive Heart Disease
NCT07544888Phase 1Completed
- Sponsor
- Shaikh Zayed Hospital
- Start
- Nov 2025
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of hydrochlorothiazide in hypertensive heart disease (2 arms), sponsored by Shaikh Zayed Hospital. Primary endpoint: Treatment Effectiveness at 8 weeks. Started Nov 2025; status: completed.
02
Drugs
hydrochlorothiazide
03
Conditions
hypertensive heart disease
Beyond the preview
Go deeper on NCT07544888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07544888.